title: Merck ends trial of potential Alzheimer's drug verubecestat.
authors.affiliation: London.
authors.forename: Nigel
authors.initials: N
authors.lastname: Hawkes
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D000682:Amyloid / Q000134:cerebrospinal fluid / Q000187:drug effects; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003499:Cyclic S-Oxides / Q000494:pharmacology / Q000627:therapeutic use*; D004345:Drug Industry / Q000379:methods; D006801:Humans; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013829:Thiadiazines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000682:Amyloid; D061067:Antibodies, Monoclonal, Humanized; D003499:Cyclic S-Oxides; D018697:Nootropic Agents; D013829:Thiadiazines; C000600266:aducanumab; C000613570:verubecestat